Sistema de Salut de Catalunya
Institut Català de la Salut
[Mirallas O, Garcia-Alvarez A, Hernando J, Capdevila J] Servei d’Oncologia Mèdica, Unitat de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Filippi-Arriaga F] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernandez Hernandez I, Biagetti B] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chaachou A, Martínez-Saez E] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-06-02T08:33:20Z
2022-06-02T08:33:20Z
2021-11-11
Agressive pituitary tumors; Capecitabine; Temozolomide
Tumores hipofisarios agresivos; Capecitabina; Temozolomida
Tumors hipofisaris agressius; Capecitabina; Temozolomida
Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
Article
Published version
English
Adenoma - Tractament; Hipòfisi - Tumors - Tractament; Quimioteràpia combinada; DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Pituitary Neoplasms::ACTH-Secreting Pituitary Adenoma::Nelson Syndrome; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias hipofisarias::adenoma hipofisario secretor de ACTH::síndrome de Nelson; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma
Frontiers Media
Frontiers in Endocrinology;12
https://doi.org/10.3389/fendo.2021.731631
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
